Peptides researched for mitochondrial dysfunction
Peptides studied for cristae stabilisation, mitokine signalling and NAD⁺-axis preservation.
Overview
Mitochondrial dysfunction is one of the most clearly characterised hallmarks of biological ageing. Aged mitochondria show reduced respiratory-chain efficiency, oxidised cardiolipin in the inner membrane, disorganised cristae structure, lower NAD⁺/NADH ratios, and impaired calcium handling. The downstream consequences — reduced cellular ATP availability, increased reactive oxygen species generation, increased apoptotic vulnerability — connect to almost every other ageing process.
The peptide research literature has converged on three complementary intervention axes. The first is structural: SS-31/elamipretide stabilises cardiolipin in the inner mitochondrial membrane and preserves cristae architecture. The second is signalling: MOTS-c and Humanin act as mitokines, coordinating systemic stress responses through AMPK activation and direct receptor binding. The third is NAD⁺-axis preservation, which intersects with peptide biology through both direct sirtuin-modulating peptides (preclinical) and mitochondrial-membrane stabilisation that preserves NAD⁺/NADH balance.
This page surveys these three axes. The mitochondrial peptide field is one of the most mechanistically rich on this site, with SS-31 having the most-developed clinical-stage dataset of any compound covered.
The biology being targeted
Cardiolipin biology is central. The unique tetra-acyl phospholipid is concentrated almost exclusively in the inner mitochondrial membrane, where it is required for cristae structural integrity, respiratory-supercomplex assembly, and the function of multiple inner-membrane proteins (ATP synthase, adenine nucleotide translocator, cytochrome c oxidase). In aged and stressed mitochondria, cardiolipin becomes oxidised and disorganised, and cristae architecture deteriorates.
AMPK signalling is the principal MOTS-c axis. MOTS-c increases the AMP:ATP sensor activity, phosphorylates AMPK at Thr172, and engages the canonical downstream programme — increased fatty-acid oxidation, GLUT4 translocation, mitochondrial biogenesis through PGC-1α, and reduced lipogenesis. The net result resembles the metabolic adaptation produced by physical exercise.
NAD⁺ biology connects through sirtuin activity. Sirtuins are NAD⁺-dependent deacetylases that regulate mitochondrial function (SIRT3, SIRT4, SIRT5 are mitochondrial-localised); their activity declines with age in parallel with NAD⁺ levels. Peptide-axis contributions to NAD⁺ biology are primarily indirect — mitochondrial-membrane stabilisation preserves NAD⁺/NADH balance — but small-molecule NAD⁺ precursors (NMN, NR) are outside the peptide scope of this site.
Peptides researched in this protocol
The most clinically-developed mitochondrial peptide. Selectively binds inner-mitochondrial-membrane cardiolipin, stabilises cristae structure, restores ATP synthesis in damaged mitochondria. Multi-phase clinical trials (MMPOWER) in primary mitochondrial myopathy. Siegel et al. 2013 demonstrated 8-day rescue of aged-muscle physical performance in mice.
Mitochondrially-derived peptide encoded in the 12S rRNA gene. AMPK-mediated exercise-mimetic effects. Plasma levels decline with age and are reduced in type 2 diabetes. Nuclear translocation under metabolic stress modulates antioxidant-response gene expression (Kim et al. 2018).
The first mitochondrially-derived peptide identified (Hashimoto 2001). Cytoprotective and anti-apoptotic; protects neurons from amyloid-β cytotoxicity at nanomolar concentrations. Plasma levels decline ~30% across adult lifespan and are preserved in centenarian offspring.
Peptide-axis contributions to NAD⁺ biology — sirtuin substrate-mimetic peptides as structural probes, mitochondrial peptides that preserve NAD⁺/NADH ratios indirectly, and peptide-conjugate delivery strategies for NAD⁺ precursors. Heterogeneous category covered for completeness.
Stack combinations in the literature
The most-discussed combination in mitochondrial peptide research is MOTS-c + SS-31 — pairing a signalling mitokine with a structural cristae stabiliser. The two operate on orthogonal axes, making the mechanistic case for combination straightforward. No direct combination-trial data is published.
MOTS-c + small-molecule NAD⁺ precursors (NMN/NR) is widely discussed in healthspan-oriented combination protocols. The mechanistic rationale is that MOTS-c activates AMPK and PGC-1α-driven mitochondrial biogenesis while NAD⁺ precursors restore sirtuin substrate availability — addressing different bottlenecks in mitochondrial-pathway restoration.
Humanin (or HNG) + SS-31 combinations have been discussed in neurology and cardiology research contexts. Mechanistic coherence: anti-apoptotic + structural stabilisation. No completed combination-trial data.
Evidence summary
Siegel et al. 2013 (Aging Cell) — eight days of SS-31 administration restored skeletal-muscle ATP production, normalised redox state and improved fatigue resistance to young-mouse levels in aged mice. One of the most striking proof-of-mechanism observations in the longevity peptide literature.
Karaa et al. 2020 (Neurology) — MMPOWER-3 phase III randomised placebo-controlled trial in primary mitochondrial myopathy. Primary efficacy endpoint not met at week 24 but patient-reported fatigue improved on active treatment. The most-developed clinical dataset in this protocol vertical.
Lee et al. 2015 (Cell Metabolism) — original MOTS-c characterisation, demonstrating prevention of diet-induced obesity and improvement of insulin sensitivity through AMPK activation in mice.
Reynolds et al. 2021 (Nature Communications) — MOTS-c administration restored age-impaired physical capacity in aged mice and partially reproduced the molecular signature of exercise training in skeletal muscle.
Safety profile & UK regulatory framing
SS-31 has the most-extensive human safety dataset of any peptide on this site, from its multi-phase clinical-trial programme. Most common adverse events are injection-site reactions and mild transient gastrointestinal upset. No mutagenic, hepatotoxic or nephrotoxic signals.
MOTS-c and Humanin rodent toxicology is favourable; human translational safety data is limited to plasma-level observational work and small-scale pilot administration studies.
Under UK law, none of these compounds holds MHRA authorisation. SS-31/elamipretide is in active clinical development with the MHRA aware of trial activity; limited expanded-access provision exists in some jurisdictions for primary mitochondrial myopathy. Research-grade material falls under the standard laboratory-and-research-use-only framing.
Frequently asked questions
Are mitochondrial peptides anti-ageing?
The mechanistic case is strong — mitochondrial dysfunction is a hallmark of biological ageing and these compounds reliably restore mitochondrial function in aged or stressed cells and tissues. The clinical translation to human anti-ageing or lifespan-extension outcomes is not established by completed trial data. Healthspan-relevant effects (physical performance, metabolic flexibility) are better-supported.
Is SS-31 a longevity drug?
Not in any regulator-recognised sense. SS-31/elamipretide is in clinical development for specific disease indications (primary mitochondrial myopathy, dry AMD). It does not hold marketing authorisation for healthy-ageing or longevity applications. The Siegel et al. 2013 aged-muscle rescue paper is the strongest single piece of mechanistic evidence supporting a longevity interpretation.
How does MOTS-c differ from exercise?
MOTS-c is described as an exercise-mimetic because it reproduces parts of the molecular signature of endurance training (AMPK activation, GLUT4 translocation, PGC-1α-mediated mitochondrial biogenesis). The breadth and magnitude of exercise's effects on cardiovascular, musculoskeletal, neurocognitive and metabolic outcomes substantially exceed what MOTS-c administration reproduces.
Should MOTS-c be combined with NMN?
The combination is widely discussed in healthspan research-protocol literature. The mechanistic case rests on orthogonal axes — MOTS-c activates AMPK/PGC-1α-mediated mitochondrial biogenesis while NMN restores sirtuin substrate availability. No completed combination-trial data exists. NMN itself is not a peptide and is outside the primary scope of this site.